We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Microfluidic Chip Can Diagnose Latent Tuberculosis

By LabMedica International staff writers
Posted on 06 Jun 2012
A microfluidic chip has been developed that can test for latent tuberculosis infection (LTBI) and maybe faster and more reliable than current testing for the disease.

Current tests for LTB are based on detecting the release of interferon-gamma (IFN-γ), a disease-fighting chemical made by cells of the immune system, which commercially available tests require sending samples to a laboratory, and can be used just once.

Biomedical engineers at University of California, Davis (UCD; CA, USA) developed a novel approach for the assay. More...
They coated a gold wafer with short pieces of a single-stranded DNA segment known to stick specifically to IFN-γ. They then mounted the wafer in a chip that has tiny channels for blood samples. If IFN-γ is present in a blood sample, it sticks to the DNA, triggering an electrical signal that can be read by a clinician.

The scientists plan to refine the system so that the microfluidic sensor and electronic readout are integrated on a single chip. An electrochemical biosensor for simple and sensitive detection of IFN-γ will have future applications in immunology, cancer research, and infectious disease monitoring. The team has already conducted testing of blood samples from patients in China and the USA. About one-third of the world's population is infected with the bacteria that cause tuberculosis, a disease that kills an estimated 1.5 million people worldwide every year, according to the US Centers for Disease Control and Prevention (CDC; Atlanta GA, USA).

Most infected people have latent TB, in which the bacteria are kept in check by the immune system. Patients become sick only when the immune system is compromised, enabling the bacteria to become active. People infected with the human immunodeficiency virus (HIV) are at especially high risk. Alexander Revzin, PhD, a professor in the UC Davis Department of Biomedical Engineering and his specialist Ying Liu, PhD, added, "Our assay is cheaper than other interferon-gamma release assays, is reusable, and gives results in real time. If you see that the IFN-γ level is high, you can diagnose latent TB."

Related Links:

University of California at Davis
US Centers for Disease Control and Prevention



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Portable POCT Blood Gas Analyzer
BD100
Electrolyte Analyzer
BKE-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers developed three mathematical biomarkers from routine PSA blood tests that may help predict early prostate cancer treatment outcomes and personalize adaptive therapy (Image Credit: Adobe Stock)

Mathematical Biomarkers Use Routine Blood Tests to Guide Adaptive Prostate Cancer Therapy

Personalizing systemic therapy for prostate cancer remains challenging because tumors can evolve under treatment pressure, driving resistance and early relapse. Continuous high-dose regimens may initially... Read more

Molecular Diagnostics

view channel
Image: The duet mosaic family comprises duet +modC mosaic and duet 6-base mosaic, two cfDNA-optimized multiomic sequencing workflows for liquid biopsy and translational research. (Photo courtesy of bimodal)

New Liquid Biopsy Workflow Maximizes Tumor Signals from Limited Blood Samples

Liquid biopsy seeks to detect tumor-derived signals from small blood samples, but circulating cell-free DNA is scarce and heterogeneous, limiting sensitivity. Combining complementary signals such as methylation,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.